Your browser doesn't support javascript.
loading
Identification of Reduced ERAP2 Expression and a Novel HLA Allele as Components of a Risk Score for Susceptibility to Liver Injury Due to Amoxicillin-Clavulanate.
Nicoletti, Paola; Dellinger, Andrew; Li, Yi Ju; Barnhart, Huiman X; Chalasani, Naga; Fontana, Robert J; Odin, Joseph A; Serrano, Jose; Stolz, Andrew; Etheridge, Amy S; Innocenti, Federico; Govaere, Olivier; Grove, Jane I; Stephens, Camilla; Aithal, Guruprasad P; Andrade, Raul J; Bjornsson, Einar S; Daly, Ann K; Lucena, M Isabel; Watkins, Paul B.
  • Nicoletti P; Department of Genetics and Genomic Science, Icahn School of Medicine at Mount Sinai, New York, New York. Electronic address: paola.nicoletti@mssm.edu.
  • Dellinger A; Duke Molecular Physiology Institute, Duke University, Durham, North Carolina.
  • Li YJ; Duke Molecular Physiology Institute, Duke University, Durham, North Carolina; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
  • Barnhart HX; Duke Molecular Physiology Institute, Duke University, Durham, North Carolina; Department of Biostatistics and Bioinformatics, Duke University, Durham, North Carolina.
  • Chalasani N; Division of Gastroenterology and Hepatology, Indiana University School of Medicine, Indianapolis, Indiana.
  • Fontana RJ; University of Michigan, Ann Arbor, Michigan.
  • Odin JA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Serrano J; National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland.
  • Stolz A; University of Southern California, Los Angeles, California.
  • Etheridge AS; University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Innocenti F; University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
  • Govaere O; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Grove JI; Nottingham Digestive Diseases Centre and National Institute for Health Research Nottingham Biomedical Research Centre at the Nottingham University Hospital National Health Service Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom.
  • Stephens C; Servicios de Digestivo y Farmacologia Clínica, Instituto de Investigación Biomédica de Málaga (IBIMA_Plataforma Bionand), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ma
  • Aithal GP; Nottingham Digestive Diseases Centre and National Institute for Health Research Nottingham Biomedical Research Centre at the Nottingham University Hospital National Health Service Trust, Nottingham, United Kingdom; University of Nottingham, Nottingham, United Kingdom.
  • Andrade RJ; Servicios de Digestivo y Farmacologia Clínica, Instituto de Investigación Biomédica de Málaga (IBIMA_Plataforma Bionand), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ma
  • Bjornsson ES; Department of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland; Faculty of Medicine, University of Iceland, Reykjavik, Iceland.
  • Daly AK; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom.
  • Lucena MI; Servicios de Digestivo y Farmacologia Clínica, Instituto de Investigación Biomédica de Málaga (IBIMA_Plataforma Bionand), Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Ma
  • Watkins PB; University of North Carolina Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; University of North Carolina Institute for Drug Safety Sciences, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Gastroenterology ; 164(3): 454-466, 2023 03.
Article en En | MEDLINE | ID: mdl-36496055
ABSTRACT
BACKGROUND &

AIMS:

Drug-induced liver injury (DILI) due to amoxicillin-clavulanate (AC) has been associated with HLA-A∗0201, HLA-DRB1∗1501, and rs2476601, a missense variant in PTPN22. The aim of this study was to identify novel risk factors for AC-DILI and to construct a genetic risk score (GRS).

METHODS:

Transcriptome-wide association study and genome-wide association study analyses were performed on 444 AC-DILI cases and 10,397 population-based controls of European descent. Associations were confirmed in a validation cohort (n = 133 cases and 17,836 population-based controls). Discovery and validation AC-DILI cases were also compared with 1358 and 403 non-AC-DILI cases.

RESULTS:

Transcriptome-wide association study revealed a significant association of AC-DILI risk with reduced liver expression of ERAP2 (P = 3.7 × 10-7), coding for an aminopeptidase involved in antigen presentation. The lead eQTL single nucleotide polymorphism, rs1363907 (G), was associated with AC-DILI risk in the discovery (odds ratio [OR], 1.68; 95% CI, 1.23-1.66; P = 1.7 × 10-7) and validation cohorts (OR, 1.2; 95% CI, 1.04-2.05; P = .03), following a recessive model. We also identified HLA-B∗1518 as a novel AC-DILI risk factor in both discovery (OR, 4.19; 95% CI, 2.09-8.36; P = 4.9 × 10-5) and validation (OR, 7.78; 95% CI, 2.75-21.99; P = .0001) cohorts. GRS, incorporating rs1363907, rs2476601, HLA-B∗1518, HLA-A∗0201, and HLA-DRB1∗1501, was highly predictive of AC-DILI risk when cases were analyzed against both general population and non-AC-DILI control cohorts. GRS was the most significant predictor in a regression model containing known AC-DILI clinical risk characteristics and significantly improved the predictive model.

CONCLUSIONS:

We identified novel associations of AC-DILI risk with ERAP2 low expression and with HLA-B∗1518. GRS based on the 5 risk variants may assist AC-DILI causality assessment and risk management.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad Hepática Inducida por Sustancias y Drogas / Antibacterianos Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad Hepática Inducida por Sustancias y Drogas / Antibacterianos Tipo de estudio: Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Año: 2023 Tipo del documento: Article